Zurich Cantonal Bank
CLDX icon

Zurich Cantonal Bank’s Celldex Therapeutics CLDX Stock Holding History

Zurich Cantonal Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,317
Closed -$688K – 2766
2025
Q4 		$688K Buy
+25,317
New +$667K ﹤0.01% 1577

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Zurich Cantonal Bank's CLDX Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 30,677 shares worth $973K. The stake represents ﹤0.01% of the portfolio and ranks #1449 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in CLDX as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in CLDX in Q2 2014 and has held it in 34 quarters since. The position peaked at $4.04M in Q4 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Zurich Cantonal Bank held 30,677 shares of Celldex Therapeutics worth $973K as of Q1 2026.
  • Celldex Therapeutics was a new Zurich Cantonal Bank position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1449 holding.
  • Zurich Cantonal Bank first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 34 quarters since.
  • Zurich Cantonal Bank's Celldex Therapeutics position peaked at $4.04M in Q4 2015.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.